NZHR has over several years repeatedly called for investment in health research to be substantially increased. However, government investment in health research has historically stagnated somewhere between about 0.6% and 0.8% of government health care costs and in the absence of any indications to the contrary is forecast to fall to 0.51% after 2025/26 when…

NZHR’s Chief Executive Chris Higgins was the lead presenter at this event alongside HRC Chief Executive Sunny Collings, MBIE Chief Science Advisor Gary Evans, and the Prime Minister’s Chief Science Advisor Juliet Gerrard. Our presentation focussed on the role of health research in addressing New Zealand’s amenable and non-amenable premature mortality figures including inequitable outcomes…

Click here to read the latest newsletter

Click here to read the latest newsletter

Click here to read the latest newsletter

Research Professional is Research Professional is an online database of research funding opportunities and a source of international research policy and practice news. This media outlet has for some time been presenting NZHR views to their subscribers both in New Zealand and internationally, and their coverage of our engagement with health research stakeholders re the…

Click here to read NZHR’s “Future Pathways for Health and Medical Research” discussion paper

NZHR has made a submission on the health reforms Bill. We set out our concerns about the New Zealand health system’s apparent historical indifference to the most fundamental of health outcomes – the country’s high and increasing levels of premature mortality – coupled with a longstanding systemic resistance to embracing health research and innovation as…

Click here to read the 2021 Annual Report of New Zealanders for Health Research

Despite references in the Hazardous Substances and New Organisms (HSNO) Act to “rapid assessment” the reality is that the process of gaining approval to develop and use genetically modified organisms (GMOs) typically takes months. Clinical research organisations which are developing new GMO based therapies for hitherto untreatable or hard to treat conditions, which have secured…